EUVIMEDEUVIMED entdecken
Crossref

Optimized Bilosome Delivery System for Dasatinib: Formulation, Characterization, and Pharmacokinetic Evaluation

Ahmed Hamed Salman, Shaimaa Nazar Abd Alhammid

Pharmaceutical Sciences · 31.07.2026 · 32 (3) · 469-478

DOI: 10.34172/ps.43430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Sciences, online erschienen am 31.07.2026. Verfasst von Ahmed Hamed Salman und 1 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dasatinib (DST), a second-generation tyrosine kinase inhibitor, suffers from poor aqueous solubility and pH-dependent absorption, limiting its oral bioavailability. Bilosomes—vesicular carriers stabilized with bile salts—offer enhanced stability in the gastrointestinal tract and improved drug encapsulation compared to conventional liposomes and niosomes. In this study, a DST-loaded bilosome (DST-LB) formulation was developed and its solubility, dissolution, and bioavailability were evaluated.

Methods

Bilosomes were prepared using the reverse-phase evaporation method and optimized via Box–Behnken design. The formulation was characterized for particle size, zeta potential, entrapment efficiency, and morphology. Capsules were evaluated for weight variation, content uniformity, dissolution, and stability. Pharmacokinetic studies were conducted in rabbits and analyzed using non-compartmental modeling.

Results

The optimized bilosomes exhibited a mean particle size of 113 nm, a polydispersity index of 0.11, a zeta potential of –22 mV, and an entrapment efficiency of 81%. Capsules showed excellent flowability and uniformity. Dissolution studies showed a sustained-release profile governed by non-Fickian transport (n=0.725), whereas the marketed tablet displayed a faster release profile following first-order kinetics (n=0.450). In vivo, bilosomes achieved higher Cmax (477.8 ng/mL vs. 374.4 ng/mL), shorter Tmax (1 h vs. 1.5 h), and greater AUC (2886.5 ng·h/mL vs. 2107.7 ng·h/mL), indicating that the systemic exposure was 38% higher with bilosomes compared to the marketed tablet. Stability testing confirmed first-order degradation with a predicted shelf life of 2.1 years.

Conclusion

DST-LB significantly enhanced dissolution, absorption, and bioavailability compared to the marketed tablet, supporting its potential as a modified-release oral delivery system for improved therapeutic outcomes.

Zitieren

APA

Salman, A. H., & Alhammid, S. N. A. (2026). Optimized Bilosome Delivery System for Dasatinib: Formulation, Characterization, and Pharmacokinetic Evaluation. Pharmaceutical Sciences, 32(3), 469-478. https://doi.org/10.34172/ps.43430

Vancouver

Salman AH, Alhammid SNA. Optimized Bilosome Delivery System for Dasatinib: Formulation, Characterization, and Pharmacokinetic Evaluation. Pharmaceutical Sciences. 2026;32(3):469-478. doi:10.34172/ps.43430

BibTeX
@article{Salman2026,
  author = {Salman, Ahmed Hamed and Alhammid, Shaimaa Nazar Abd},
  title = {Optimized Bilosome Delivery System for Dasatinib: Formulation, Characterization, and Pharmacokinetic Evaluation},
  journal = {Pharmaceutical Sciences},
  year = {2026},
  volume = {32},
  number = {3},
  pages = {469--478},
  doi = {10.34172/ps.43430}
}
Kostenlos starten →